Month: May 2024

Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both trials now expected by end of third and fourth quarter of 2024, respectively Reported positive proof-of-concept for lonigutamab in thyroid eye disease patients and positive top-line Phase 2b/3 data for izokibep in psoriatic arthritis Cash, cash equivalents, and short-term marketable securities at March 31, 2024 of $678.5 million Company also announced changes to leadership team LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) — ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today provided an update on various corporate milestones. “Our top priority...

ST. GALLEN, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company, today announced that Carsten Koerl, Chief Executive Officer, will participate in the J.P. Morgan 52nd Annual Global Technology, Media and Communications Conference at the Westin Boston Seaport District Hotel on Tuesday, May 21, 2024. Mr. Koerl will participate in a fireside chat at 8:10 a.m. EST that morning and that will be webcast live on https://investors.sportradar.com. Please contact your J.P. Morgan sales representative to register for the conference and to request a meeting with Sportradar management. About SportradarSportradar Group AG (NASDAQ: SRAD), founded in 2001, is a leading global sports technology company creating immersive experiences for sports...

WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, announced today that the management team will participate in The Citizens JMP Life Sciences Conference on May 13, 2024. The Aquestive management team will hold a fireside chat on May 13 at 11:30 am ET and will host investor meetings. A webcast of the fireside chat will be available on the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com. About AquestiveAquestive is a pharmaceutical company advancing medicines...

Bio-Equity Europe 2024 Asebio Investor Day 2024 RSC Hot Topics: Covalent Drug Discovery Foro Medcap BME 2024MADRID, Spain and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in May. Oryzon will attend Bio-Equity Europe 2024, which will be held at the Kursaal Elkargunea Center in San Sebastián (Spain) on May 12-14. The company will provide a corporate update on May 13 at 15:15 CET and will hold one-on-one meetings with global investors and pharmaceutical companies. Click on the link for more info about Bio-Equity Europe 2024 Oryzon has...

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced that it will present at the B. Riley 24th Annual Institutional Investor Conference, which is being held May 22-23, 2024 at the Beverly Hilton Hotel in Beverly Hills, California. Derek Dubner, Chief Executive Officer, and Dan MacLachlan, Chief Financial Officer, are scheduled to participate in an analyst-led discussion on Wednesday, May 22, 2024, at 9:00 a.m. PT, in addition to hosting one-on-one meetings with interested investors. Investors wishing to schedule a one-on-one meeting should contact their B. Riley representative. About red violet® At red violet, we build proprietary technologies and apply analytical capabilities to deliver identity intelligence. Our technology powers...

AUBURN HILLS, Mich., May 09, 2024 (GLOBE NEWSWIRE) — SPAR Group, Inc. (NASDAQ: SGRP) (“SPAR”, “SPAR Group” or the “Company”), a leading global provider of merchandising and marketing services, today announces that it will release its 2024 fiscal first quarter results on Wednesday, May 15, 2024, before the market opens. In conjunction with the release, a conference call will be hosted by Mike Matacunas, Chief Executive Officer; and Antonio Calisto Pato, Chief Financial Officer, and will include a Q&A session following the prepared remarks starting at 10:00 am Eastern.By Phone: Dial 1-833-630-1542, or 1-412-317-1821 if calling from an International number, at least 10 minutes before the call and ask to be joined into the SPAR Group call. A replay will be available through May 22nd by dialing 1-877-344-7529 and using the conference...

ROUYN-NORANDA, Quebec, May 09, 2024 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Company”) (TSX Venture : ABI) is pleased to confirm a second gold mineralized zone East of the Flordin deposit toward the Cartwright deposit 100% owned by Abcourt. Highlights• A petrographic study confirms the presence of gold grains in the pyrite. These gold grains would be associated with the second phase of pyrite crystallization.• Compilation work has shown that the gold is not only contained in quartz veins and veinlets but also in sheared and altered zones, which are mineralized in disseminated pyrite.• The historical hole S-158 published in 1988 by Cambior Inc. intersected 3 g/t gold over 16 m in an altered, pyrite-mineralized zone without quartz veins (south zone).• The compilation work allows...

– FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension – BOSTON and ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company has received final meeting minutes from its recent pre-IND meeting with the Division of Cardiology and Nephrology of the U.S. Food and Drug Administration (FDA) for IkT-001Pro (“Pro”) as a candidate treatment for Pulmonary Arterial Hypertension (PAH). Following review of the final meeting minutes,...

Earnings Results to be Released on Thursday, May 30, After the Close of the Market SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, will release third quarter fiscal year 2024 earnings after the market closes on Thursday, May 30, 2024. The company will host an investor conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the results.Date: Thursday, May 30th, 2024Time: 1:30 p.m. PTWebcast: https://ir.zscaler.comDial-in: To join by phone, register at the following link: Click Here. After registering, you will be provided with a dial-in number and a personal PIN that you will need to join the call.Please dial in at least 10 minutes prior to the 1:30 p.m. PT start time. A live webcast of the conference call will be accessible...

Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients. MARLBOROUGH, Mass. and FRANKFURT, Germany, May 09, 2024 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma patients, announced an exclusive agreement today under which the parties will develop market opportunities for combining Akoya’s PhenoImager HT platform and NeraCare’s Immunoprint assay for patient stratification and therapy selection in early-stage melanoma patients. Melanoma is the leading cause of skin cancer-related deaths, with over 235,000...